Aerocrine provides update on its legal action against Apieron

Aerocrine provides update on its legal action against Apieron

SOLNA, Sweden - 7 April 2010 - Aerocrine AB today announced that its patent
infringement cases in the U.S. and Europe against Apieron Inc., Menlo Park, USA
will be stayed as a result of Apieron filing for Chapter 7 bankruptcy.

Following Apieron's 2008 launch of its Insight™ exhaled NO device in the U.S.,
Aerocrine filed complaints against Apieron for infringing three U.S. patents. 
Apieron subsequently filed a counterclaim in that case, asserting that Aerocrine
infringes two patents that Apieron purchased in 2004.  Apieron also filed a
complaint against Aerocrine in Germany in July 2009 for alleged infringement of
the German counterpart to one of the U.S. patents.  In a 2003 License and
Settlement Agreement, however, Aerocrine settled a dispute about the same
patents asserted by Apieron with the previous owners of these patents.

Apieron filed a Chapter 7 bankruptcy petition in the United States Bankruptcy
Court for the Northern District of California on 30 March. As a result,
Aerocrine's organization may now fully focus on commercial and scientific
development in the U.S.

Aerocrine has applied for and received numerous patents that protect its
inventions for monitoring airway inflammation by measuring exhaled NO.  “Patents
constitute an important prerequisite for companies such as ours to make the long
term and pioneering investments in product and market development required to
bring innovations to the benefit of patients,” said Paul de Potocki, CEO of
Aerocrine AB.  “While we favor business resolutions to matters related to patent
disputes, we will continue to forcefully defend our company's intellectual
property.”

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 80

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. The pioneer and leader
in the technology to monitor and manage airway inflammation, Aerocrine markets
NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable
measurement of airway inflammation and may thus play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
8:00 am on April the 7th 2010.